A renewed spotlight is forming around small-cap healthcare companies as U.S. policy shifts toward accelerating research into psychedelic-based therapies for mental health disorders. Following the recent executive order, several companies are drawing increased investor and industry attention.
Atai Life Sciences (NASDAQ: ATAI) is positioned at the forefront of psychedelic drug development through its Atai-Beckley platform, focused on rapid-acting and durable treatments for mental health disorders. The company’s pipeline includes BPL-003 (mebufotenin benzoate nasal spray) targeting treatment-resistant depression, currently in Phase 3 planning, alongside VLS-01 (DMT buccal film) and EMP-01 ((R)-MDMA HCl) in Phase 2 development. The company is also advancing non-hallucinogenic 5-HT2A receptor agonists.
Compass Pathways (NASDAQ: CMPS) is leading psilocybin clinical development through its COMP360 program for treatment-resistant depression. The therapy has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the United Kingdom.
Psyence Biomedical (NASDAQ: PBM) is strengthening its position in the emerging ibogaine market through collaboration with PsyLabs, establishing an integrated, GMP-compliant manufacturing platform spanning sourcing, extraction, purification, and pharmaceutical production. With direct access to raw materials in Africa, the company is focused on ensuring traceability, supply continuity, and sustainability.
ENDRA Life Sciences (NASDAQ: NDRA), while not a psychedelic drug developer, is increasingly emerging as a critical player supporting healthcare infrastructure as clinical trial demand expands. Its TAEUS liver imaging technology is designed to measure liver fat for metabolic dysfunction-associated steatotic liver disease conditions affecting more than two billion people globally. The company is also reviewing strategic alternatives aimed at expanding growth pathways. ENDRA closed at $6.40 on approximately $488,000 in dollar volume on April 19, 2026, marking a 96.3% gain over the past 30 days.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/abnewswire-2026-4-20-small-cap-medical-stocks-atai-cmps-ndra-pbm-in-focus-as-us-policy-accelerates-psychedelic-research